146 related articles for article (PubMed ID: 31622099)
41. A novel benzenediamine derivate rescued mice from experimental sepsis by attenuating proinflammatory mediators via IRAK4.
Dou H; Song Y; Liu X; Yang L; Jiang N; Chen D; Li E; Tan R; Hou Y
Am J Respir Cell Mol Biol; 2014 Aug; 51(2):191-200. PubMed ID: 24588661
[TBL] [Abstract][Full Text] [Related]
42. 4-Quinazolinyloxy-diaryl ureas as novel BRAFV600E inhibitors.
Holladay MW; Campbell BT; Rowbottom MW; Chao Q; Sprankle KG; Lai AG; Abraham S; Setti E; Faraoni R; Tran L; Armstrong RC; Gunawardane RN; Gardner MF; Cramer MD; Gitnick D; Ator MA; Dorsey BD; Ruggeri BR; Williams M; Bhagwat SS; James J
Bioorg Med Chem Lett; 2011 Sep; 21(18):5342-6. PubMed ID: 21807507
[TBL] [Abstract][Full Text] [Related]
43. Interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitors: an updated patent review (2016-2018).
McElroy WT
Expert Opin Ther Pat; 2019 Apr; 29(4):243-259. PubMed ID: 30916602
[TBL] [Abstract][Full Text] [Related]
44. Discovery of highly potent, selective, and efficacious small molecule inhibitors of ERK1/2.
Ren L; Grina J; Moreno D; Blake JF; Gaudino JJ; Garrey R; Metcalf AT; Burkard M; Martinson M; Rasor K; Chen H; Dean B; Gould SE; Pacheco P; Shahidi-Latham S; Yin J; West K; Wang W; Moffat JG; Schwarz JB
J Med Chem; 2015 Feb; 58(4):1976-91. PubMed ID: 25603482
[TBL] [Abstract][Full Text] [Related]
45. MYD88 L265P mutation promoted malignant B cell resistance against T cell-mediated cytotoxicity via upregulating the IL-10/STAT3 cascade.
Qiu H; Gong S; Xu L; Cheng H; Gao L; Chen J; Hu X; Yang J
Int Immunopharmacol; 2018 Nov; 64():394-400. PubMed ID: 30253331
[TBL] [Abstract][Full Text] [Related]
46. Establishing and Validating Cellular Functional Target Engagement Assay for Selective IRAK4 Inhibitor Discovery.
Chen Y; Sun D; Yang R; Lim J; Sondey C; Presland J; Rakhilina L; Addona G; Kariv I; Chen H
SLAS Discov; 2021 Sep; 26(8):1040-1054. PubMed ID: 34130529
[TBL] [Abstract][Full Text] [Related]
47. Synthesis and SAR of 1-acetanilide-4-aminopyrazole-substituted quinazolines: selective inhibitors of Aurora B kinase with potent anti-tumor activity.
Foote KM; Mortlock AA; Heron NM; Jung FH; Hill GB; Pasquet G; Brady MC; Green S; Heaton SP; Kearney S; Keen NJ; Odedra R; Wedge SR; Wilkinson RW
Bioorg Med Chem Lett; 2008 Mar; 18(6):1904-9. PubMed ID: 18294849
[TBL] [Abstract][Full Text] [Related]
48. Clinicopathologic significance of MYD88 L265P mutation in diffuse large B-cell lymphoma: a meta-analysis.
Lee JH; Jeong H; Choi JW; Oh H; Kim YS
Sci Rep; 2017 May; 7(1):1785. PubMed ID: 28496180
[TBL] [Abstract][Full Text] [Related]
49. Click chemistry for improvement in selectivity of quinazoline-based kinase inhibitors for mutant epidermal growth factor receptors.
Song J; Jang S; Lee JW; Jung D; Lee S; Min KH
Bioorg Med Chem Lett; 2019 Feb; 29(3):477-480. PubMed ID: 30554954
[TBL] [Abstract][Full Text] [Related]
50. High frequency and clinical prognostic value of MYD88 L265P mutation in primary cutaneous diffuse large B-cell lymphoma, leg-type.
Pham-Ledard A; Beylot-Barry M; Barbe C; Leduc M; Petrella T; Vergier B; Martinez F; Cappellen D; Merlio JP; Grange F
JAMA Dermatol; 2014 Nov; 150(11):1173-9. PubMed ID: 25055137
[TBL] [Abstract][Full Text] [Related]
51. Design of a Novel and Selective IRAK4 Inhibitor Using Topological Water Network Analysis and Molecular Modeling Approaches.
Lee MH; Balupuri A; Jung YR; Choi S; Lee A; Cho YS; Kang NS
Molecules; 2018 Nov; 23(12):. PubMed ID: 30501110
[TBL] [Abstract][Full Text] [Related]
52. Inhibitors of interleukin-1 receptor-associated kinase 4 (IRAK4): a patent review (2012-2015).
Seganish WM
Expert Opin Ther Pat; 2016 Aug; 26(8):917-32. PubMed ID: 27310003
[TBL] [Abstract][Full Text] [Related]
53. Identification of 4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline derivatives as a new class of orally and selective Polo-like kinase 1 inhibitors.
Beria I; Ballinari D; Bertrand JA; Borghi D; Bossi RT; Brasca MG; Cappella P; Caruso M; Ceccarelli W; Ciavolella A; Cristiani C; Croci V; De Ponti A; Fachin G; Ferguson RD; Lansen J; Moll JK; Pesenti E; Posteri H; Perego R; Rocchetti M; Storici P; Volpi D; Valsasina B
J Med Chem; 2010 May; 53(9):3532-51. PubMed ID: 20397705
[TBL] [Abstract][Full Text] [Related]
54. 4,5-Dihydro-1H-pyrazolo[4,3-h]quinazolines as potent and selective Polo-like kinase 1 (PLK1) inhibitors.
Beria I; Valsasina B; Brasca MG; Ceccarelli W; Colombo M; Cribioli S; Fachin G; Ferguson RD; Fiorentini F; Gianellini LM; Giorgini ML; Moll JK; Posteri H; Pezzetta D; Roletto F; Sola F; Tesei D; Caruso M
Bioorg Med Chem Lett; 2010 Nov; 20(22):6489-94. PubMed ID: 20932759
[TBL] [Abstract][Full Text] [Related]
55. Acquisition of MYD88 L265P mutation during treatment of diffuse large B cell lymphoma of the parotid gland.
Fujiishi K; Kitazawa R; Nagai Y; Watanabe T; Bando K; Kobayashi S; Yakushijin Y; Haraguchi R; Kitazawa S
Virchows Arch; 2014 Jan; 464(1):121-4. PubMed ID: 24259032
[No Abstract] [Full Text] [Related]
56. [MyD88 L265P mutation and B cell tumor].
Chen HM; Hou J
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2014 Feb; 22(1):241-4. PubMed ID: 24598687
[TBL] [Abstract][Full Text] [Related]
57. Crystal structure of human IRAK1.
Wang L; Qiao Q; Ferrao R; Shen C; Hatcher JM; Buhrlage SJ; Gray NS; Wu H
Proc Natl Acad Sci U S A; 2017 Dec; 114(51):13507-13512. PubMed ID: 29208712
[TBL] [Abstract][Full Text] [Related]
58. CD79B and MYD88 mutations in diffuse large B-cell lymphoma.
Kim Y; Ju H; Kim DH; Yoo HY; Kim SJ; Kim WS; Ko YH
Hum Pathol; 2014 Mar; 45(3):556-64. PubMed ID: 24444466
[TBL] [Abstract][Full Text] [Related]
59. Discovery and structure-activity relationship of novel diphenylthiazole derivatives as BTK inhibitor with potent activity against B cell lymphoma cell lines.
Guo X; Yang D; Fan Z; Zhang N; Zhao B; Huang C; Wang F; Ma R; Meng M; Deng Y
Eur J Med Chem; 2019 Sep; 178():767-781. PubMed ID: 31234030
[TBL] [Abstract][Full Text] [Related]
60. Novel approaches to targeting MYD88 in Waldenström macroglobulinemia.
Castillo JJ; Hunter ZR; Yang G; Treon SP
Expert Rev Hematol; 2017 Aug; 10(8):739-744. PubMed ID: 28617062
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]